Navigation Links
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Date:3/12/2008

ne million men in the United States have prostate cancer, with an estimated 186,320 new cases expected to be diagnosed in 2008, and approximately 28,660 men expected to die this year from the disease. Currently there are limited treatment options for men with advanced, metastatic prostate cancer.

About Active Cellular Immunotherapy with PROVENGE

PROVENGE may represent the first product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. In clinical studies, patients typically received three doses of PROVENGE over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
2. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
3. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
4. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
5. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
8. ExonHit and bioMerieux Amend Their Strategic Partnership
9. Halozyme Therapeutics Amends Stockholder Rights Plan
10. Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
11. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 Amgen (NASDAQ: ... Directors today declared a $0.61 per share dividend for ... paid on Sept. 5, 2014, to all stockholders of ... 14, 2014.  About Amgen Amgen is ... suffering from serious illnesses by discovering, developing, manufacturing and ...
(Date:7/25/2014)... According to a new market report published ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 ... at USD 161,056.5 million in 2014 and is expected ... to 2020, to reach an estimated value of USD ... is witnessing a significant growth due to the increasing ...
(Date:7/25/2014)... , July 25, 2014  Galmed Pharmaceuticals Ltd. ... company focused on the development and commercialization of a ... and cholesterol gallstones, today announced financial results for the ... 2014 Financial Summary: , Reported cash and cash ... with $137,000 at December 31, 2013.  , Reported ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4
... BEIJING , May 10 /PRNewswire-Asia-FirstCall/ -- Yongye International, Inc.,(Nasdaq: ... Shengmingsu brand plant and animal nutrient products in the,People,s Republic of ... four investment conferences in May 2010 . , ... The date, time and ...
... BEIJING , May 10 /PRNewswire-Asia-FirstCall/ -- Yongye International, Inc.,(Nasdaq: ... distributor of Shengmingsu brand plant and animal nutrient products in ... has started,the construction of a new production facility in Wuchuan County, ... , , ...
... ... LASIK Surgeons launched its revolutionary Trusted LASIK Surgeons directory service and website ... seeking to improve their vision and find a highly qualified eye surgeon ... sets the Trusted LASIK Surgeons directory apart is a unique screening process ...
Cached Biology Technology:Yongye International to Present at Upcoming Investor Conferences 2Yongye International to Present at Upcoming Investor Conferences 3Yongye International, Inc. Begins Construction of New Production Facility 2Yongye International, Inc. Begins Construction of New Production Facility 3Yongye International, Inc. Begins Construction of New Production Facility 4Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 2Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 3Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 4Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 5Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 6Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 7Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 8Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 9
(Date:7/27/2014)... RESEARCH UK scientists at Barts Cancer Institute have found ... cancer therapy significantly more effective, according to research published ... Barts Cancer Institute, part of Queen Mary University of ... kinase (FAK), signals the body to repair itself after ... DNA. When the researchers removed FAK from blood vessels ...
(Date:7/25/2014)... 25, 2014 In the first broad-scale estimate of air ... and collaborators calculated that trees are saving more than ... of acute respiratory symptoms. , While trees, pollution removal ... than 1 percent, the impacts of that improvement are ... reduced air pollution at nearly $7 billion every year ...
(Date:7/25/2014)... been raging this summer and some of the smoke from ... this image collected by the Moderate Resolution Imaging Spectroradiometer (MODIS) ... of smoke has descended over the Great Lakes region of ... fire image from July 23, 2014 (first image feature highlighted ... drifts off southeastward. In the image, it is over ...
Breaking Biology News(10 mins):New drug target can break down cancer's barrier against treatment 2First national study finds trees saving lives, reducing respiratory problems 2
... Sheng Yang He, plant biologist at Michigan State ... plant scientists as part of a $75 million new ... Institute and the Gordon and Betty Moore Foundation honored ... and 14 other researchers from around the country. The ...
... Spring Harbor, N.Y. The Howard Hughes Medical Institute (HHMI) ... selected Professor Rob Martienssen, Ph.D., of Cold Spring Harbor ... basic research in fundamental plant science. Dr. Martienssen is ... scientists who have been named HHMI-GBMF Investigators in plant ...
... Md. (June 16, 2011) Coaches, physiologists and athletes ... before athletic competition. Warming up increases muscle temperature, accelerates ... which enhance performance. However, the question of how long ... with some in the sports community advocating longer warm-ups ...
Cached Biology News:MSU plant scientist named one of the nation's most innovative researchers 2CSHL professor Rob Martienssen receives prestigious appointment as HHMI-GBMF investigator 2CSHL professor Rob Martienssen receives prestigious appointment as HHMI-GBMF investigator 3CSHL professor Rob Martienssen receives prestigious appointment as HHMI-GBMF investigator 4When warming up for the cycling race, less is more 2When warming up for the cycling race, less is more 3
Request Info...
IHC Detection Kit (Broad Spectrum AEC)....
... Dissociation Buffers are membrane-filtered isotonic and ... agents and cell-conditioning agents in either ... solution or Ca2+- and Mg2+-free ... mammalian cells from support substrates and ...
Request Info...
Biology Products: